• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Etoposide Teva
    / Abic


    Active Ingredient
    Etoposide 20 mg/ml

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 X 100 mg / 5 ml

    partial basket chart 35132 5538

    Vial

    1 X 200 mg / 10 ml

    partial basket chart 35133 5539

    Vial

    1 X 1000 mg / 50 ml

    partial basket chart 75921 5589

    Dosage

    Etoposide must not be given by intra-cavity injection.
    Dose adjustments: Dosage of etoposide should be modified to take into account the myelosuppressive effects of other drugs in the combination or the effects of prior X-ray therapy or chemotherapy which may have compromised bone marrow reserve.
    Etoposide is administered by slow intravenous infusion. ETOPOSIDE SHOULD NOT BE ADMINISTERED BY RAPID INTRAVENOUS INJECTION.
    Hypotension following rapid intravenous administration of etoposide has been reported. Therefore, it is recommended that the etoposide injection be administered by slow i. v. infusion over a 30 to 60-minute period. Longer infusion times may be required based on patient tolerance. As with other potentially toxic compounds, caution should be exercised in handling and preparing the solution of etoposide. Skin reactions associated with accidental exposure to etoposide may occur. The use of gloves is recommended. If etoposide solution contacts the skin or mucosa, immediately wash the skin or mucosa thoroughly with soap and water.
    Patients should not begin a new cycle of treatment with etoposide if the neutrophil count is less than 1,500 cells/mm3 or the platelet count is less than 100,000 cells/mm3, unless caused by malignant disease.
    Doses subsequent to the initial dose should be adjusted if neutrophil count less than 500 cells/mm3 occurs for more than 5 days or is associated with fever or infection, if platelet count less than 25,000 cells/mm3 occurs, if any other grade 3 or 4 toxicity develops or if renal clearance is less than 50 ml/min.
    Renal impairment: See prescribing information.
    Testicular Tumors, Hodgkin’s Disease, Malignant (non-Hodgkin’s) Lymphomas-Especially of the Histiocytic Variety, Acute Non-Lymphocytic Leukemia: The usual dose of etoposide, in combination with other approved chemotherapeutic agents, ranges from 50-100 mg/m2/day on days 1 through 5 to 100 mg/m2/day on days 1, 3, and 5.
    Small Cell Lung Cancer: The usual dose of etoposide, in combination with other approved chemotherapeutic drugs, ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.
    Chemotherapy courses should be repeated at 3 to 4-week intervals after adequate recovery from any toxicity.
    The dosage should be modified to take into account the myelosuppressive effects of other drugs in the combination, or the effects of prior x-ray therapy or chemotherapy which may have compromised bone marrow reserve.


    Indications

    Etoposide is indicated for the management of:
    – Refractory Testicular Tumors: Etoposide injection in combination therapy with other approved chemotherapeutic agents in patients with refractory testicular tumors who have already received appropriate surgical,
    chemotherapeutic and radiotherapeutic therapy.
    – Small Cell Lung Cancer: Etoposide injection in combination with other approved chemotherapeutic agents as first line
    treatment.
    – Hodgkin’s Disease
    – Malignant (non-Hodgkin’s) Lymphomas, Especially of the Histiocytic Variety
    – Acute Non-Lymphocytic Leukemia


    Contra-Indications

    Severe myelosuppression, unless when this is caused by the underlying disease.
    Severe hepatic impairment.
    Hypersensitivity to etoposide or one of the other constituents.
    Breastfeeding.
    Concomitant use of yellow fever vaccine or other live vaccines is contraindicated in immunosuppressed patients.


    Manufacturer
    Pharmachemie, Teva Group (S.L.E)
    CLOSE